Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Suspended Not applicable Interventional Accepts healthy volunteers

Insulin Resistance Study

NCT00614757
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome x
Interventions
N-acetylcysteine 20% 4ml, N-acetylcysteine 20% in 4 ml
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 29, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

NCT00381433
View directory record Official record
Conditions
Encephalitis
Interventions
AVI-4065 Injection
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

NCT02120300
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

HCV Positive Heart Donors

NCT03382847
View directory record Official record
Conditions
Heart Failure
Interventions
Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 29, 2026, 7:59 AM EDT
Completed No phase listed Observational

Collection of Liver Tissue for Virologic Studies

NCT00005936
View directory record Official record
Conditions
Virus Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 7:59 AM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

NCT00963885
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 29, 2026, 7:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT04046107
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
Cemiplimab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

NCT00394277
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

NCT02581592
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

NCT00395421
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
NM283 plus Peg-IFNα-2a
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Timeline
2006 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

NCT01051921
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, Pegylated interferon, Ribavirin
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
La Jolla, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 29, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

NCT01335230
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic, HCV Coinfection
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

NCT00502788
View directory record Official record
Conditions
Hepatitis C, Thalassemia
Interventions
Peginterferon Alfa-2a and Ribavirin, Ribavirin
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 44 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 29, 2026, 7:59 AM EDT
Not listed Not applicable Interventional

Vitamin A Supplementation in Preterm Infants

NCT00063596
View directory record Official record
Conditions
Infant, Premature
Interventions
Vitamin A supplementation
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 3 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 29, 2026, 7:59 AM EDT
Completed No phase listed Observational

Anticipated and Perceived Benefits Following Hepatitis C Treatment

NCT03000023
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers

NCT03596697
View directory record Official record
Conditions
Hepatitis B, Infectious Disease, Liver Diseases
Interventions
CRV431, Placebo, TDF
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tempe, Arizona • Lincoln, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 29, 2026, 7:59 AM EDT
Terminated Phase 1 Interventional

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

NCT00277758
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 29, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System

NCT03898349
View directory record Official record
Conditions
Hepatitis C
Interventions
Annie text messaging system, Annie text messaging system with Usual implementation, Annie text messaging system with Augmented implementation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 7:59 AM EDT